ABSTRACT
El propósito de este trabajo fue el de investigar la frecuencia de alteraciones moleculares en el gen MTAP y su codeleción con los genes supresores de tumores p15INK4b y p16INK4a en osteosarcoma humano. Se analizaron 96 osteosarcomas humanos y tres líneas celulares. Se estudió la incidencia de codeleción en MTAP, p15INK4b y p16INK4a con el DNA, y la expresión de RNA y de proteínas. Se halló deleción de MTAP en un 37,5 por ciento de los casos y en una de las tres líneas celulares, estando codelecionado con el exon 1 de p15INK4b.En ningún caso con deleción de MTAP se observó presencia de mRNA o de proteína. En cuatro casos se observó deleción en el gen de MTAP en el transcurso de la enfermedad. En la línea celular HOS se apreció diez veces más sensibilidad a quimioterápicos que actúan en la vía de síntesis de novo de las purinas. El gen de MTAP está comúnmente delecionado en pacientes con osteosarcoma. Estos resultados indican que los inhibidores que actúan en la vía de síntesis de novo de las purinas o bien la depleción de metionina pueden ser medidas efectivas en el tratamiento de pacientes con osteosarcomas cuyos tumores no expresen el gen de la MTAP (AU)
Subject(s)
Adolescent , Adult , Female , Male , Child , Humans , Osteosarcoma/genetics , Genes, Tumor Suppressor/genetics , Purine-Nucleoside Phosphorylase/genetics , Gene Deletion , Gene ExpressionABSTRACT
En este artículo pretendemos analizar los conocimientos actuales sobre las bases moleculares de la carcinogénesis y su aplicación en el cáncer oral. La biología molecular, ha contribuido en gran medida con la etiología del cáncer, ya que ha permitido dilucidar los mecanismos genéticos por los que una célula se transforma y adquiere un fenotipo maligno. En el cromosoma de una célula existen genes (protooncogenes), implicados en los procesos normales de crecimiento, maduración y proliferación celular. En ocasiones, estos protooncogenes pueden sufrir alteraciones que provocan una alteración en la función normal. A estos genes se les conoce como oncogenes. Nosotros describimos las proteínas más importantes producidas por los oncogenes, así como, los genes supresores del cáncer, poniendo especial atención en el gen p53 (AU)
Subject(s)
Humans , Oncogenes/genetics , Genes, Tumor Suppressor/genetics , Apoptosis/genetics , Mouth Neoplasms/genetics , Cell Division , Cell DifferentiationABSTRACT
The molecular pathogenesis of B cell chronic lymphocytic leukemia (B-CLL), the most common form of leukemia, remains unknown. We have used the mRNA differential display technique to analyze genes that may be involved in the development/progression of B-CLL. We have identified the tumor suppressor retinoic acid receptor responder 3 (RARRES3) as a B-CLL-related gene. RARRES3 maps to chromosome band 11q23, a region frequently deleted in lymphoproliferative disorders. To assess the potential involvement of RARRES3 in leukemogenesis, we examined 24 cases of B-CLL, 10 of acute lymphocytic leukemia (ALL) and five related cell lines by RT-PCR and sequence analyses. We report a correlation between RARRES3 down-regulation and B-CLL progression. We also found decreased RARRES3 gene levels in ALL cases and in the five cell lines studied. We did not find mutations in any of the leukemia samples assayed, including those with 11q23 deletion. These results indicate that RARRES3 may play a role in B-CLL progression.
Subject(s)
Genes, Tumor Suppressor/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/etiology , Receptors, Retinoic Acid/genetics , Adolescent , Adult , Aged , Amino Acid Sequence , Cell Line, Transformed , Child , Chromosomes, Human, Pair 11/genetics , Down-Regulation , Female , Gene Expression , Gene Expression Profiling , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Male , Middle Aged , Molecular Sequence Data , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sequence AlignmentABSTRACT
Ovarian cancer is the fourth most common cancer in women. Its pronostic is dreadful and, in spite of numerous studies, the steps of ovarian carcinogenesis are unclear. Histologically, three sub-types of ovarian tumors (benign, borderline and invasive) are distinguished, suggesting the existence of a continuum. However, as each sub-type presents its own biologic characteristics, the hypothesis of the progression of a pre-neoplastic precursor (benign or borderline tumor) into an invasive tumor is still open to discussion. Numerous molecular biological studies have been conducted on ovarian tumors, with the aims of identifying their molecular abnormalities and better understanding the process of ovarian carcinogenesis. Synthesis of the published data (concerning oncogene amplification and/or surexpression, loss of heterozygosity, tumor suppressor gene inactivation, microsatellite instability) shows that there are numerous abnormalities, confirming the heterogeneity and the complexity of these tumors. Hence, it remains very difficult to draw a scheme of ovarian carcinogenesis. Nevertheless, in a near future the new technology of laser microdissection may improve the quality of the results and the study of early ovarian lesions. Indeed, with this technique, it becomes possible to isolate well-defined and homogeneous cell populations and to study small or architecturally complex (surface lesions) tumors. In the next years, the results obtained may allow the identification of early events of the ovarian carcinogenesis and the development of diagnostic and therapeutic tools.
Subject(s)
Ovarian Neoplasms/genetics , DNA, Neoplasm/genetics , Female , Forecasting , Gene Expression Regulation, Neoplastic , Genes, Tumor Suppressor/genetics , Genetic Predisposition to Disease/genetics , Humans , Loss of Heterozygosity , Microsatellite Repeats/genetics , Ovarian Neoplasms/pathologyABSTRACT
Loss of heterozygosity for a locus on human chromosome 11q22-23 is observed at high frequency in non-small cell lung carcinoma (NSCLC). Introduction of a 1.1 Mb fragmented yeast artificial chromosome (YAC) mapping to this region completely suppresses the tumorigenic properties of a human NSCLC cell line, A549. Smaller fragmented YACs give partial but not complete suppression. To further localize the gene(s) responsible for this partial suppression, a bacterial artificial chromosome (BAC) and P1-based artificial chromosome (PAC) contig was constructed, completely spanning the candidate region. End sequence generated in the construction of the BAC/PAC contig identified a previously unmapped EST and served to order genomic sequence contigs from the publicly available Celera Genomics (CG) and Human Genome Project (HGP) efforts. Comparison showed that CG provided larger contigs, while HGP provided more coverage. Neither CG nor HGP provided complete sequence coverage, alone or in combination. The sequence was used to map 110 ESTs and to predict new genes, including two GenScan gene predictions that overlapped ESTs and were shown to be differentially expressed in tumorigenic and suppressed A549 cell lines.
Subject(s)
Chromosomes, Human, Pair 11/genetics , Genes, Tumor Suppressor/genetics , Genetic Predisposition to Disease/genetics , Immunoglobulins , Membrane Proteins , Proteins/genetics , Cell Adhesion Molecule-1 , Cell Adhesion Molecules , Contig Mapping , DNA, Neoplasm/chemistry , DNA, Neoplasm/genetics , Humans , Molecular Sequence Data , Physical Chromosome Mapping , Sequence Analysis, DNA , Tumor Cells, Cultured , Tumor Suppressor ProteinsABSTRACT
Risk-reduction mastectomy (RRM), also known as bilateral prophylactic mastectomy, is a controversial clinical option for women who are at increased risk of breast cancer. High-risk women, including women with a strong family history of breast cancer and BRCA1/2 mutation carriers, have several clinical options: risk-reduction surgery (bilateral mastectomy and bilateral oophorectomy), surveillance (mammography, clinical breast examination, and breast self-examination), and chemoprevention (tamoxifen). We review research in a number of areas central to our understanding of RRM, including recent data on 1) the effectiveness of RRM in reducing breast cancer risk, 2) the perception of RRM among women at increased risk and health-care providers, 3) the decision-making process for follow-up care of women at high risk, and 4) satisfaction and psychological status after surgery. We suggest areas of future research to better guide high-risk women and their health-care providers in the decision-making process.
Subject(s)
Breast Neoplasms/prevention & control , Breast Neoplasms/surgery , Mastectomy , Mutation , Anticarcinogenic Agents/therapeutic use , Attitude to Health , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/epidemiology , Breast Neoplasms/genetics , Breast Neoplasms/psychology , Decision Making , Estrogen Receptor Modulators/therapeutic use , Female , Genes, BRCA1/genetics , Genes, Tumor Suppressor/genetics , Heterozygote , Humans , Incidence , Mammography , Ovariectomy , Population Surveillance/methods , Raloxifene Hydrochloride/therapeutic use , Risk , Tamoxifen/therapeutic useABSTRACT
BACKGROUND: Analysis of high-risk prostate cancer (PC) families with at least one confirmed case of primary brain cancer (BC) has identified a region of genetic linkage on chromosome 1p36 termed CAPB. The p36 region of chromosome one has been reported to have frequent loss of heterozygosity (LOH) in brain and central nervous system (CNS) tumors and epidemiological studies have shown an increased relative risk of BC and tumors of the CNS in PC families. In 1997 a reported tumor suppressor with high homology to p53, termed p73, was mapped to the p36 region of chromosome one. Here, we examine the p73 gene as a potential candidate for CAPB. METHODS: Ninety-four members from the 12 prostate-brain cancer families in which linkage was originally found were examined. The complete coding region and intron-exon boundaries of the p73 gene were analyzed for germline mutations by Single Stranded Conformational Polymorphism analysis (SSCP) and direct DNA sequencing. RESULTS: Silent nucleotide substitutions only were detected within the coding regions of the gene in affected individuals. Nucleotide changes were detected in introns 1, 6, 8, 9, and 10, but all were located >or=16 base pairs from the splice site, and are thus unlikely to be deleterious mutations. CONCLUSIONS: Germline mutations in the p73 gene are unlikely to be critical for inherited susceptibility to PC in this specified subset of families.
Subject(s)
Brain Neoplasms/genetics , DNA-Binding Proteins/genetics , Genes, Tumor Suppressor/genetics , Germ-Line Mutation , Nuclear Proteins/genetics , Prostatic Neoplasms/genetics , Aged , Aged, 80 and over , DNA, Neoplasm/genetics , Female , Genetic Linkage , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Polymerase Chain Reaction , Polymorphism, Single-Stranded Conformational , Tumor Protein p73 , Tumor Suppressor ProteinsABSTRACT
PTEN tumor suppressor is frequently mutated in human cancers and is a negative regulator of PI3'K/PKB/Akt-dependent cellular survival. Investigation of the human genomic PTEN locus revealed a p53 binding element directly upstream of the PTEN gene. Deletion and mutation analyses showed that this element is necessary for inducible transactivation of PTEN by p53. A p53-independent element controlling constitutive expression of PTEN was also identified. In contrast to p53 mutant cell lines, induction of p53 in primary and tumor cell lines with wild-type p53 increased PTEN mRNA levels. PTEN was required for p53-mediated apoptosis in immortalized mouse embryonic fibroblasts. Our results reveal a unique role for p53 in regulation of cellular survival and an interesting connection in tumor suppressor signaling.
Subject(s)
Phosphoric Monoester Hydrolases/genetics , Phosphoric Monoester Hydrolases/metabolism , Promoter Regions, Genetic , Transcription, Genetic , Transcriptional Activation , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins , Animals , Apoptosis/physiology , Cell Line , Embryo, Mammalian/cytology , Fibroblasts/physiology , Gamma Rays , Genes, Reporter , Genes, Tumor Suppressor/genetics , Genes, p53 , Humans , Immunoblotting , Mice , Molecular Sequence Data , PTEN Phosphohydrolase , Temperature , Transfection , Tumor Suppressor Protein p53/geneticsABSTRACT
Cell cycle defects have been associated with the process of carcinogenesis in many studies. Here we report the cloning and analysis of the novel gene KIAA0008 (GenBank acc. no. D13633). Chromosomal localization experiments assigned the gene to chromosome 14q22-q23. The mRNA transcript was found to be cell cycle regulated, expressed at S-phase, and maintained at both G2-and M-phases. In situ hybridization showed expression in proliferating colon and breast (tumor) tissues. Structurally, KIAA0008 shares homology with the Drosophila melanogaster discs large-1 (dlg1) tumor suppressor gene and membrane-associated guanylate kinase protein family members. The potential involvement of KIAA0008 in cell proliferation is discussed, along with its sequence identity and tissue distribution.
Subject(s)
Cell Cycle/physiology , Genes, Tumor Suppressor/genetics , Proteins/genetics , Adaptor Proteins, Signal Transducing , Animals , Blotting, Northern , Breast Neoplasms/genetics , Chromosome Mapping , Chromosomes, Human, Pair 14/genetics , Colonic Neoplasms/genetics , Discs Large Homolog 1 Protein , Drosophila melanogaster/genetics , Female , Gene Expression Regulation , Gene Expression Regulation, Neoplastic , HeLa Cells , Humans , In Situ Hybridization , Male , Membrane Proteins , Neoplasm Proteins , RNA/genetics , RNA/metabolism , Tissue DistributionABSTRACT
Database searches identified on chromosome 22q11.2, a region subject to translocations, an homologue of the HIC1 (hypermethylated in cancer) candidate tumor suppressor gene located at 17p13.3. This gene was termed HRG22 for HIC1-related gene on chromosome 22. We have characterized a new HRG22 upstream coding exon and defined the complete coding sequence of the human and zebrafish HRG22 genes. Alignment of the HRG22 and HIC1 proteins from various species revealed high sequence homology in their N-terminal BTB/POZ and five C-terminal C(2)H(2) zinc finger domains and highlighted a conserved GLDLSKK/R peptide in their middle region. The full-length HRG22 and HIC1 proteins colocalize onto nuclear dots and share several functional properties since their BTB/POZ domains heterodimerize and are autonomous transcriptional repression domain insensitive to Trichostatin A, a histone deacetylase (HDAC) inhibitor. Thus, HIC1 and HRG22 define a subgroup of BTB/POZ domains unable to recruit repressing complexes containing an HDAC activity.
Subject(s)
Carrier Proteins/genetics , Chromosomes, Human, Pair 22 , DNA-Binding Proteins , Genes, Tumor Suppressor/genetics , Transcription Factors/genetics , Tumor Suppressor Proteins , Amino Acid Sequence , Animals , Base Sequence , Cell Nucleus/metabolism , Chromosome Mapping , Conserved Sequence , Gene Expression/drug effects , Genome, Human , Humans , Hydroxamic Acids/pharmacology , Kruppel-Like Transcription Factors , Molecular Sequence Data , Protein Structure, Tertiary , Sequence Homology, Amino Acid , Transcription Factors/chemistry , Zebrafish , Zebrafish ProteinsABSTRACT
Previous loss-of-heterozygosity studies in endometrial carcinoma mapped a putative tumor suppressor gene to 10q25.3-26.1. An analysis of genomic sequences for the deletion interval showed several expressed sequence tags and the homeodomain gene EMX2, a homologue of Drosophila melanogaster empty spiracles. Expression studies showed that EMX2 transcripts are abundant in the adult uterus and that message levels seem to be inversely correlated with endometrial proliferation. EMX2 RNA was more abundant in quiescent postmenopausal endometrium than in premenopausal endometrium. We found decreased EMX2 expression in a subset of primary endometrial tumors, and four of six endometrial cancer cell lines investigated failed to express EMX2. The predicted protein showed extensive amino acid conservation with EMX2 sequences from several vertebrates. There was also considerable evolutionary conservation in the 3' untranslated region. To examine the potential function of EMX2 in endometrial tumorigenesis, we investigated 20 primary tumors and 6 endometrial cancer cell lines for mutations. Two primary tumors had mutations. Inactivation or reduced expression of EMX2 in cancers, coupled with increased expression in the quiescent endometrium, indicate that this homeodomain gene is involved in maintenance of the differentiated state.
Subject(s)
Conserved Sequence/genetics , Endometrial Neoplasms/genetics , Genes, Homeobox/genetics , Homeodomain Proteins/biosynthesis , Homeodomain Proteins/genetics , Adenocarcinoma/genetics , Amino Acid Sequence , Base Sequence , DNA Mutational Analysis/methods , DNA, Neoplasm/genetics , Evolution, Molecular , Female , Gene Expression Profiling , Genes, Tumor Suppressor/genetics , Humans , Mixed Tumor, Mullerian/genetics , Molecular Sequence Data , Mutation/genetics , Polymorphism, Genetic/genetics , Transcription Factors , Tumor Cells, CulturedABSTRACT
Pancreatic endocrine tumors (PETs) occur in association with multiple endocrine neoplasia type 1 (MEN1) and von Hippel-Lindau (VHL) syndromes caused by germline alterations in MEN1 and VHL, respectively. It is thus expected that these genes will also be altered in a proportion of sporadic PETs. Indeed, MEN1 is altered in about 25% of nonfamilial PETs, although no mutations have been found in VHL. For all clinical subtypes, the frequency of allelic loss on chromosome arm 11q mirrors observed mutational frequencies, with the exception of nonfunctional tumors (NF-PETs), in which mutations have been reported in only 8% of cases. As allelic loss on 11q is the most frequent event found in these neoplasms, this low frequency is somewhat puzzling, particularly in light of the fact that most MEN1-associated PETs are nonfunctioning. To clarify the role of these genes in sporadic PETs, we analyzed 31 sporadic NF-PETs, nine insulinomas, and one VIPoma for alterations in MEN1 and VHL. As somatic mutations were observed in eight (26%) of the NF tumors and in one insulinoma, it would therefore appear unlikely that an additional tumor suppressor gene related to sporadic PET pathogenesis is located on 11q. One insulinoma also had a somatic mutation in VHL, and thus this gene may also be altered in these neoplasms, albeit in a small proportion of cases.
Subject(s)
Genes, Tumor Suppressor/physiology , Ligases/genetics , Multiple Endocrine Neoplasia Type 1/genetics , Pancreatic Neoplasms/genetics , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , von Hippel-Lindau Disease/genetics , Genes, Tumor Suppressor/genetics , Humans , Ligases/physiology , Multiple Endocrine Neoplasia Type 1/etiology , Pancreatic Neoplasms/etiology , Von Hippel-Lindau Tumor Suppressor Protein , von Hippel-Lindau Disease/etiologyABSTRACT
Chromosome 13q14 deletions constitute the most common genetic abnormality in chronic lymphocytic leukemia (CLL). To identify the putative tumor suppressor gene targeted by 13q14 genomic loss, we completely sequenced and characterized a segment of 790 kb at 13q14 spanning the minimal region of loss in CLL. Transcribed sequences in the region were identified through database homology searches and exon-prediction analysis. Two-hundred kb at the centromeric end of the sequence contain five CpG islands, three previously identified genes LEU5/RFP2, LEU2, and LEU1, seven of seven EST clusters composed of >10 ESTs, and a large number of predicted exons. Homology searches against the mouse EST database have allowed us to identify a highly conserved alternative first exon of the LEU2 gene, giving rise to a novel transcript, ALT1 (GenBank accession no. AF380424), which originates within a G+C region in the vicinity of the D13S272 marker. Two novel 3' exons of LEU2 were also identified and are present in both LEU2 and ALT1 transcripts. However, we have not identified any mutations in leukemia cases, or alterations in expression of mRNAs in the region, that might directly implicate these mRNAs in the pathology of CLL. The centromeric end of the sequence, where all reported genes are located, contains twice the expected amount of ALU repeats, whereas the telomeric end is LINE1 rich and contains four LINE1 elements longer than 4 kb, including two full-length LINE1 sequences. This feature of the sequence may favor the occurrence of chromosomal rearrangements and may confer instability to the region, resulting in deletions that may inactivate an as yet unidentified tumor suppressor.
Subject(s)
Chromosomes, Human, Pair 13/genetics , Genes, Tumor Suppressor/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Proteins/genetics , Alternative Splicing , Animals , Base Sequence , Expressed Sequence Tags , Humans , Mice , Molecular Sequence Data , RNA, Long Noncoding , RNA, Messenger/genetics , Sequence Homology, Nucleic Acid , Transcription, Genetic , Transferases , Tumor Cells, Cultured , Tumor Suppressor ProteinsABSTRACT
Allelic deletion or transcriptional silencing of RASSF1, a putative tumor suppressor at 3p21.3, has been found in a considerable proportion of lung, breast, and ovarian cancers. In this study, we analyzed the expression and mutation status of three RASSF1 isoforms (-A, -B, and -C) in 55 primary bladder carcinomas and 10 bladder and prostate cancer cell lines. The RASSF1A transcript was not found in 80% (4 of 5) and 100% (4 of 4) of bladder and prostate cell lines, respectively. Compared with normal bladder tissues, loss or significant reduction of RASSF1A was identified in 62% (34 of 55) of primary bladder carcinomas and 10 (83%) of 12 matched sets showed tumor-specific alteration of RASSF1A expression. Moreover, loss or abnormal down-regulation of RASSF1A correlated with advanced tumor stage. RASSF1B was undetectable in 60% (3 of 5) of bladder cell lines and in 31% (17 of 55) of primary tumors, but none of these tumors showed altered expression exclusively in RASSF1B. RASSF1C transcript was detected in all cell lines and primary tumors we examined. Expression of RASSF1A and RASSF1B was reactivated in all nonexpressor cell lines by treatment with the demethylating agent 5-aza-2'-deoxycytidine. Bisulfite DNA sequencing analysis revealed that aberrant hypermethylation at the CpG island in the RASSF1A promoter is strongly associated with the loss of RASSF1A expression in cell lines and uncultured primary tumors. Methylation-specific PCR and BstUI digestion analyses also demonstrated that 97% (33 of 34) of RASSF1A-nonexpressing primary tumors are methylated. Although somatic mutations were not identified in RASSF1 transcripts expressed in unmethylated tumors, 24% (9 of 37) of methylated cell lines and primary tumors showed detectable reductions in genomic levels of RASSF1, suggesting that RASSF1A inactivation might be caused by both epigenetic and genetic mechanisms in a subset of bladder tumors. Together, our data suggest that RASSF1A inactivation may play a critical role in the malignant progression of human bladder carcinomas.
Subject(s)
Gene Silencing , Neoplasm Proteins/genetics , Tumor Suppressor Proteins , Urinary Bladder Neoplasms/genetics , Adult , Base Sequence , Chromosomes, Human, Pair 3 , CpG Islands/genetics , DNA Methylation , Down-Regulation , Female , Gene Expression Regulation, Neoplastic , Genes, Tumor Suppressor/genetics , Humans , Loss of Heterozygosity , Male , Middle Aged , Molecular Sequence Data , Neoplasm Proteins/biosynthesis , Promoter Regions, Genetic , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Tumor Cells, Cultured , Urinary Bladder Neoplasms/metabolismABSTRACT
To determine the pathogenic role of chromosomes 11 and 17 in the carcinogenesis of human ovarian cancers, neo(R)-tagged chromosome 11 or 17 was transferred from cell lines A9H11 or A9H17, respectively, into the ovarian carcinoma cell line SKOV-3 using microcell-mediated chromosome transfer. The chromosome transfer was verified by polymerase chain reaction detection of the neo(R) gene, fluorescence in situ hybridization detection of an extra chromosome 11, and microsatellite polymorphism detection of an exogeneous chromosome 11. Five SKOV-3/A9H11 hybrids and five SKOV-3/A9H17 hybrid clones were generated. For the chromosome 11 transfer, complete suppression of tumorigenicity was observed in four clones, (11)9-8 and 11(H)7-2, 11(H)8-3, and 11(H)7-2, 100 days post implantation. For the chromosome 17 transfer, no complete suppression of tumorigenicity was observed. However, an increased latency period ranging from 25 to 49 days in contrast to 7 days for the SKOV-3 parental line, and a significant reduction in tumor size was observed. There was no correlation between the in vitro growth rate and the tumorigenicity or length of latency period. Our results demonstrate functionally that chromosome 11 may carry a tumor suppressor gene(s) while chromosome 17 may carry a tumor growth-inhibitor gene(s) for the ovarian carcinoma cell line, SKOV-3.
Subject(s)
Carcinoma/genetics , Chromosomes, Human, Pair 11/genetics , Gene Transfer Techniques , Genes, Tumor Suppressor/genetics , Ovarian Neoplasms/genetics , Animals , Cell Division/genetics , Chromosomes, Human, Pair 17/genetics , Clone Cells , Disease Progression , Female , Genetic Markers , Humans , In Situ Hybridization, Fluorescence , Mice , Mice, SCID , Neoplasm Transplantation , Polymerase Chain Reaction , Time Factors , Tumor Cells, CulturedABSTRACT
Hepatocellular carcinoma (HCC) is one of the most frequent-occurring malignant tumours worldwide, but molecular changes of tumour DNA, with the exception of viral integrations and p53 mutations, are poorly understood. In order to search for common macro-imbalances of genomic tumour DNA, 21 HCCs and 3 HCC-cell lines were characterized by comparative genomic hybridization (CGH), subsequent database analyses and in selected cases by fluorescence in situ hybridization (FISH). Chromosomal subregions of 1q, 8q, 17q and 20q showed frequent gains of genomic material, while losses were most prevalent in subregions of 4q, 6q, 13q and 16q. Deleted regions encompass tumour suppressor genes, like RB-1 and the cadherin gene cluster, some of them previously identified as potential target genes in HCC development. Several potential growth- or transformation-promoting genes located in chromosomal subregions showed frequent gains of genomic material. The present study provides a basis for further genomic and expression analyses in HCCs and in addition suggests chromosome 4q to carry a so far unidentified tumour suppressor gene relevant for HCC development.
Subject(s)
Carcinoma, Hepatocellular/genetics , Chromosome Deletion , Liver Neoplasms/genetics , Translocation, Genetic , Female , Genes, Tumor Suppressor/genetics , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Male , Tumor Cells, CulturedABSTRACT
OBJECTIVE: Tumors arising from different sites of the head and neck area have different clinical behavior. However, most of the studies on genetic alterations in head and neck squamous cell carcinomas do not make a distinction between the sites within this area. The objective of this study is to compare the genetic alterations in three different sites of the head and neck (larynx, oropharynx, and hypopharynx). STUDY DESIGN: Prospective study. METHODS: Thirty-eight laryngeal, 29 oropharyngeal, and 37 hypopharyngeal carcinomas were studied. DNA from tumor and healthy tissue was evaluated for amplification of the oncogenes at 11q13 region (CCND1, FGF3, FGF4 and EMS1) and of the oncogenes MYC and ERBB1; for integration of the human papillomavirus (HPV) types 6b and 16; for loss of heterozygosity (LOH) at p53 and NAT2; and for the cellular DNA content. RESULTS: FGF3 and FGF4 showed a significantly higher frequency of amplification in hypopharyngeal tumors (P =.006 and P =.0002, respectively). CCND1 amplification had a nearly statistically significant (P =.072) higher frequency of amplification in hypopharyngeal tumors. Aneuploid tumors were found in a significantly lower proportion in the larynx (P =.03) compared with the other sites. For the other genetic alterations, no significant differences among the three sites were found. CONCLUSIONS: These results suggest that cancers originating from different sites in the head and neck may have different tumor biology. Therefore, they should be considered as different entities.
Subject(s)
Carcinoma, Squamous Cell/genetics , Head and Neck Neoplasms/genetics , Aneuploidy , Carcinoma, Squamous Cell/pathology , DNA, Neoplasm/genetics , Data Interpretation, Statistical , Female , Flow Cytometry , Genes, Tumor Suppressor/genetics , Head and Neck Neoplasms/pathology , Humans , Hypopharyngeal Neoplasms/genetics , Hypopharyngeal Neoplasms/pathology , Laryngeal Neoplasms/genetics , Male , Middle Aged , Nucleic Acid Amplification Techniques , Oncogenes/genetics , Oropharyngeal Neoplasms/genetics , Oropharyngeal Neoplasms/pathology , Polymerase Chain Reaction , Prospective StudiesABSTRACT
Five years ago the fragile histidine triad (FHIT) gene including the most common fragile site locus of the human genome, FRA3B, was identified. The gene is altered in many types of cancer and several data support the idea that FHIT has to be considered a tumor suppressor. FHIT abnormalities were investigated in some skin tumors. Fifty-seven per cent of Merkel cell carcinomas displayed abnormal FHIT products but the involvement of FHIT in human non-melanoma skin cancer is still unclear. Because the murine Fhit locus is similar to its human homologue and is altered in cancer cell lines, we have established a strain of Fhit-deficient mice. After N-nitrosomethylbenzylamine treatment, the spectrum of tumors developed by the Fhit-deficient mice was similar to those observed in a familial skin cancer condition, the Muir-Torre syndrome, although there is no clear evidence yet for a relationship of FHIT and the human syndrome. Because cancer cells lacking in FHIT are defective in apoptosis, we propose the Fhit-deficient mouse as a model to understand a possible proapoptotic mechanism deficiency in the human syndrome.
Subject(s)
Acid Anhydride Hydrolases , Neoplasm Proteins , Proteins/genetics , Skin Neoplasms/genetics , Animals , Apoptosis/genetics , Disease Models, Animal , Genes, Tumor Suppressor/genetics , Humans , Skin Neoplasms/pathologyABSTRACT
The deficiencies of nucleotide excision repair (NER) factors are involved in rare genetic diseases such as xeroderma pigmentosum (XP) with increased risk of developing cancer on sun-exposed areas of the skin. However, the abnormality of NER factors in human sporadic carcinoma remains unclear. Loss of heterozygosity (LOH) analysis, using the microdissected tissues, for the XPA, XPB, XPC, XPD, XPE, XPF, XPG and the transcription-coupled repair factor, Cockayne syndrome B (CSB) revealed that NER factors were abnormal in 30.0% (3/10 cases) of oral squamous cell carcinomas. Furthermore, 10.0% of oral carcinomas exhibited LOH for NER factors without LOH for tumor suppressor genes such as p53, FHIT, APC, BRCA1, BRCA2 and DCC. These observations raise the possibility that alterations of NER factors may be involved in carcinogenesis in human oral squamous cell carcinoma.
Subject(s)
Carcinoma, Squamous Cell/genetics , Cell Adhesion Molecules/genetics , DNA Repair/genetics , DNA-Binding Proteins/genetics , Loss of Heterozygosity , Mouth Neoplasms/genetics , Protozoan Proteins , Carcinoma, Squamous Cell/etiology , Chromosome Deletion , DNA, Neoplasm/analysis , Genes, Tumor Suppressor/genetics , Humans , Microsatellite Repeats , Mouth Neoplasms/etiologyABSTRACT
BACKGROUND: BRCA1 and BRCA2 are the two major susceptibility genes involved in hereditary breast cancer. This study was undertaken to provide reliable population-based estimates of genetic influence and to characterize the nature and prevalence of BRCA1 and BRCA2 germline mutations in early-onset breast cancer. METHODS: In a series comprising all women diagnosed with breast cancer under the age of 41 years in southern Sweden during 1990 through 1995 (n = 262), family history of cancer was evaluated in 95% (n = 250) of the case subjects and germline mutations in BRCA1 and BRCA2 were analyzed in 89% (n = 234). All statistical tests were two-sided. RESULTS: A total of 97 case subjects had at least one first- or second-degree relative with breast or ovarian cancer; 34 (14%; 95% confidence interval [CI] = 9.6% to 18%) cases had at least two first- or second-degree relatives, 22 (8.8%; 95%CI = 5.3% to 12%) had one first-degree relative, and 41 (16%; 95% CI = 12% to 21%) had one second-degree relative with either cancer. If two females affected with breast or ovarian cancer who were related through an unaffected male were also defined as first-degree relatives, then a higher number of case subjects, 120 (48%; 95% CI = 42% to 54%), had at least one first-degree or second-degree relative with breast or ovarian cancer. Sixteen (6.8%; 95% CI = 4.0% to 11%) BRCA1 mutation carriers and five (2.1%; 95% CI = 0.70% to 4.9%) BRCA2 mutation carriers were identified. Among case subjects with one first- or more than one first- or second-degree relative with breast or ovarian cancer, BRCA mutations were more frequent (P<.001) than among the case subjects without this degree of family history. BRCA mutations were also statistically significantly more common among women with bilateral breast cancer than among women with unilateral breast cancer (P =.002). BRCA mutations were more common among younger case subjects than among older ones (P =.0027). CONCLUSIONS: Almost half (48%) of women in southern Sweden with early-onset breast cancer have some family history of breast or ovarian cancer, and 9.0% of early-onset breast cancer cases are associated with a germline mutation in BRCA1 or BRCA2. Mutation carriers were more prevalent among young women, women with at least one first- or second-degree relative with breast or ovarian cancer, and women with bilateral breast cancer.